FindTrial
Sign In

Prevalence and risk factors of abnormally high N-terminal pro B-type natriuretic peptide (NT-proBNP) in diabetes patients with high risk for diabetic foot ulcer.

Prevalence and risk factors of abnormally high N-terminal pro B-type natriuretic peptide (NT-proBNP) in diabetes patients with high risk for diabetic foot ulcer.

Status
Unknown
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20240425001
Enrollment
82
Registered
2024-04-25
Start date
2023-10-20
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early detection of cardiac disease in diabetic patients at high risk of foot ulcers by N-terminal pro B-type natriuretic peptide (NT-proBNP) level N-terminal pro B-type natriuretic peptide (NT-proBNP) , diabetic patients at high risk of foot ulcers, heart failure

Interventions

patients high risk diabetic foot ulcer and positive N-terminal pro B-type natriuretic peptide (NT-proBNP).,patients high risk diabetic foot ulcer and negative N-terminal pro B-type natriuretic peptide
Screening,Screening
Positive N-terminal pro B-type natriuretic peptide patients.,Negative N-terminal pro B-type natriuretic peptide patients.

Sponsors

Roche Diagnostics (Thailand) Limited
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. High risk diabetic foot ulcers patients : diagnosis criteria -Loss of Protective Sensation or Peripheral Artery Disease and one or more of the following: - history of a foot ulcer and there is a foot ulcer, the ulcer must not have an active infection. - a lower-extremity amputation (minor or major) 2. Age is over 18 years old.

Exclusion criteria

Exclusion criteria: 1. History of heart disease -myocardium infarction - heart failure or symptomatic of heart failure - constrictive pericarditis -cardiac tamponade -valvular heart disease -hypertrophic cardiomyopathy -persistent cardiac arrhythmias 2. eGFR calculated by CKD-EPI < 30 ml/min/1.732 3. Hb < 8 gm/dl 4. Assay interference If one receives medication or levels of substances that exceed the specified threshold, it may affect the NT-proBNP test results. -Bilirubin > 25 mg/dL -fasting triglyceride > 1500 mg/dL - Individuals who are taking medication containing biotin. - Rheumatoid arthritis, TB, connective tissue disease, hematologic malignancy

Design outcomes

Primary

MeasureTime frame
N-terminal pro B-type natriuretic peptide (NT-proBNP) within 12 months after included to study prevalence, elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) levels within 12 months after included to study factor—

Secondary

MeasureTime frame
cardiac abnormalities within 12 months after exam N-terminal pro B-type natriuretic peptide (NT-proBNP) echocardiogram—

Countries

Thailand

Contacts

Public ContactKongporn Noisang

Faculty of Medicine, Thammasat University

gingkaew.rosakel@gmail.com6663750616

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026